Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Glioblastoma Foundation Inc
Deal Size : Undisclosed
Deal Type : Agreement
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Details : Under the terms of the agreement, Basilea sells and transfers all rights to BAL101553 (lisavanbulin) to the Glioblastoma Foundation. It is currently being evaluated for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 20, 2024
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Glioblastoma Foundation Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Basilea Gets U.S. FDA Orphan Drug Designation for Lisavanbulin
Details : In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2017
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2016
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2015
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2011
Lead Product(s) : Lisavanbulin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
